COG NCTN Integrated Translational Science Center for Hematopoietic Malignancies in Children

COG NCTN 儿童造血系统恶性肿瘤综合转化科学中心

• 批准号: 10600096
• 负责人: SOHEIL MESHINCHI
• 金额: $ 53.53万
• 依托单位: PUBLIC HEALTH INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-03-01 至 2025-02-28
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10600096
• 关键词: Acceleration; Acute Lymphocytic Leukemia; Acute Myelocytic Leukemia; Acute Promyelocytic Leukemia; Address; Adult; Area; B-Lymphocytes; Biological; Biological Markers; Biological Sciences; Biology; Cancer Biology; Cancer Etiology; Cancer Survivor; Cause of Death; Center for Translational Science Activities; Child; Child Care; Child Support; Childhood; Childhood Leukemia; Childhood Lymphoma; Classification; Clinic; Clinical; Clinical Research; Clinical Trials; Clinical Trials Cooperative Group; Cytotoxic Chemotherapy; Data; Developmental Therapeutics Program; Diagnostic; Disease; Elements; Ensure; Eosinophilic Granuloma; Evaluation; Fostering; Funding; Generations; Genomic approach; Genomics; Goals; Grant; Guidelines; Hematologic Neoplasms; Hematopoietic; Hematopoietic Neoplasms; Heterogeneity; Hodgkin Disease; Infrastructure; Intervention; Juvenile Myelomonocytic Leukemia; Laboratories; Leadership; Link; Malignant Childhood Neoplasm; Malignant Neoplasms; Microscopy; Molecular; Morphology; Multi-Institutional Clinical Trial; Non-Hodgkin' s Lymphoma; North America; Outcome; Patients; Pediatric Neoplasm; Pediatric Oncology Group; Phase; Pilot Projects; Quality of life; Relapse; Research; Research Project Grants; Resources; Risk; Solid; Structure; Survivors; T-Lymphocyte; Therapeutic; Therapeutic Intervention; Therapeutic Trials; Therapeutic Uses; Translating; Translational Research; Translations; Treatment Efficacy; Validation; Variant; childhood cancer mortality; clinical application; clinical implementation; clinical practice; clinically actionable; clinically relevant; design; epigenomics; fundamental research; improved; improved outcome; innovation; leukemia/lymphoma; molecular diagnostics; molecular marker; new therapeutic target; novel; novel marker; operation; outcome prediction; personalized approach; pre-clinical; prevent; programs; prospective; research study; risk stratification; statistics; success; targeted treatment; therapeutic development; therapeutic target; young adult

Project Summary Hematopoietic malignancies including leukemias and lymphomas contribute to nearly half of all cancers and are a major cause of death from disease in children. The Children’s Oncology Group (COG) has spearheaded efforts to improve outcome in children with cancer, and despite dramatic improvements in survival over the last several decades, relapse remains a major problem, and survivors may suffer long term complications from the cytotoxic therapy. Better understanding of the biology of malignancies allows for more rational, targeted approaches to therapy, minimizing the need or the intensity of the non-selective cytotoxic therapies. Such targeted approaches have transformed some diseases from uniformly fatal to highly curable ones (e.g., CML, APL), but a paucity of actionable targets has prevented broader application of targeted interventions in hematopietic malignancies. As part of its focus on optimizing the survival in pediatric cancers and improving quality of life for the cancer survivors, COG through partnerships with NCI has conducted a number of discovery phase studies to identify the biologic basis of cancer in children, with the goal of identifying specific targets for more appropriate risk stratification and directed therapies in its clinical trials. With the emerging data from pediatric (and adult) discovery phase studies, COG is poised to take the next step in identifying actionable targets for therapeutic intervention. As part of these efforts, COG has created the Network Group Integrated Translational Science Centers (ITSCs) aimed at providing resources for therapeutically driven translational research. COG Hematopoietic ITSC (HM-ITSC) has put into place intellectual (leadership) and physical resources (resource laboratories, biospecimens, etc.) to ensure rapid identification of actionable targets through carefully designed translational research projects, and fostering the experimental data through a carefully structured mechanism to clinical application. HM-ITSC is structured and integrated into the functional operations of the COG, with direct links to the COG Operations Office, Disease Committees, Network group Data and Statistics Center and Developmental Therapeutics in order to facilitate rapid flow of actionable translational biology data to clinical implementation within NCTN clinical trials. Hematopoietic Malignancies (HM) are a major cause of cancer in children and novel therapeutic targets are needed to optimize outcome. COG HM-Integrated Translational Science Center, integrated into the functional organization of COG, will provide resources to support translational research in pediatric leukemias and lymphomas towards identification of clinically meaningful targets and their incorporation into clinical trials.

项目摘要 包括白血病和淋巴瘤在内的造血系统恶性肿瘤占所有癌症的近一半， 是儿童疾病死亡的主要原因。儿童肿瘤学小组（COG）率先 努力改善癌症儿童的预后，尽管在过去的几年里， 几十年来，复发仍然是一个主要问题，幸存者可能会遭受长期的并发症， 细胞毒疗法更好地了解恶性肿瘤的生物学可以更合理，更有针对性地 治疗方法，最大限度地减少非选择性细胞毒性治疗的需要或强度。等 有针对性的方法已经将一些疾病从一致致命转变为高度可治愈的疾病（例如，慢性粒细胞白血病， 但由于缺乏可操作的目标，无法更广泛地应用有针对性的干预措施， 造血系统恶性肿瘤作为其重点的一部分，优化儿童癌症的生存率， 为了提高癌症幸存者的生活质量，COG通过与NCI的合作， 发现阶段研究，以确定儿童癌症的生物学基础，目的是确定特定的 在其临床试验中更适当的风险分层和定向治疗的目标。随着新出现的数据 从儿科（和成人）发现阶段的研究中，COG准备采取下一步行动， 治疗干预的目标。作为这些努力的一部分，COG已经创建了网络组集成 翻译科学中心（ITSC）旨在为治疗驱动的翻译提供资源 research. COG造血ITSC（HM-ITSC）已将智力（领导力）和身体 资源（资源实验室、生物标本等）确保迅速确定可采取行动的目标 通过精心设计的转化研究项目，并通过 精心构建的机制，以临床应用。人力资源管理信息技术服务中心的结构和功能已纳入 COG的运营，与COG运营办公室，疾病委员会，网络组 数据和统计中心和发展治疗，以促进可操作的快速流动 转化生物学数据到NCTN临床试验中的临床实施。造血系统恶性肿瘤 (HM)是儿童癌症的主要原因，需要新的治疗靶点来优化结果。 COG HM-综合翻译科学中心，整合到COG的职能组织，将 提供资源，支持儿科白血病和淋巴瘤的转化研究， 确定有临床意义的靶点并将其纳入临床试验。